Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Trea
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 20 abstracts—including one mini oral presentation—showcasing advances in methylation-based tumor classification and liquid biopsy technology across…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.